Verona Pharma plc (VRNA) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Verona Pharma plc (VRNA) Healthcare & Pipeline Overview

Verona Pharma plc is a clinical-stage biopharmaceutical company specializing in respiratory disease therapies, with its lead candidate, ensifentrine, targeting COPD, asthma, and cystic fibrosis. Ensifentrine's unique dual-inhibitor mechanism differentiates it within the competitive respiratory market, addressing both bronchodilation and inflammation.

What Is the Investment Thesis for VRNA?

Verona Pharma's investment thesis centers on the potential of ensifentrine to become a leading treatment for respiratory diseases. The dual-inhibitor mechanism offers a differentiated approach compared to existing therapies, potentially leading to improved efficacy and patient outcomes. Positive Phase 3 trial results for COPD, expected throughout 2026, could drive significant value appreciation. The company's focus on multiple formulations (nebulizer, DPI, pMDI) expands its market reach. However, the company's negative profit margin of -37.6% and reliance on a single drug candidate represent key risks. Successful commercialization and market penetration are crucial for long-term value creation.

Based on FMP financials and quantitative analysis

VRNA Key Highlights

• Market capitalization of $72.7B reflects investor confidence in Verona Pharma's potential.
• Gross margin of 95.1% indicates strong pricing power if ensifentrine is successfully commercialized.
• Currently in Phase 3 clinical trials for ensifentrine, targeting a large and underserved respiratory disease market.
• The company's innovative dual-inhibitor mechanism of action differentiates it from existing therapies.
• Beta of 0.05 suggests low volatility relative to the overall market.

Who Are VRNA's Competitors?

VRNA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VRNA's Key Strengths?

• Novel dual-inhibitor mechanism of action.
• Phase 3 clinical trials underway for multiple respiratory indications.
• Multiple formulations (nebulizer, DPI, pMDI) to cater to different patient needs.
• Strong intellectual property protection.

What Are VRNA's Weaknesses?

• Reliance on a single drug candidate (ensifentrine).
• Negative profit margin.
• Limited commercial infrastructure.
• High R&D expenses.

What Could Drive VRNA Stock Higher?

• Publication of Phase 3 clinical trial results for ensifentrine in COPD throughout 2026.
• Potential regulatory submissions for ensifentrine in the US and Europe in late 2026 or early 2027.
• Continued enrollment and progress in Phase 3 clinical trials for asthma and cystic fibrosis.
• Potential for strategic partnerships or collaborations to expand market reach.

What Are the Key Risks for VRNA?

• Negative return on equity (-1.6%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Failure to obtain regulatory approval for ensifentrine.
• Competition from existing and emerging therapies for respiratory diseases.
• High research and development costs.
• Dependence on the success of a single drug candidate.

What Are the Growth Opportunities for VRNA?

• Expansion into Asthma Market: Ensifentrine's potential in treating asthma represents a significant growth opportunity. The global asthma market is projected to reach $25 billion by 2028, driven by increasing prevalence and unmet needs in severe asthma. Verona Pharma's clinical trials are evaluating ensifentrine's efficacy in asthma patients, and positive results could lead to regulatory approval and market entry, providing a substantial revenue stream.
• Development for Cystic Fibrosis: Cystic fibrosis (CF) presents another promising growth avenue for ensifentrine. The CF market, while smaller than COPD and asthma, is characterized by high unmet needs and premium pricing. Ensifentrine's anti-inflammatory and bronchodilator properties could benefit CF patients, and successful clinical trials could lead to orphan drug designation and accelerated approval pathways. This could provide a niche market with high profitability.
• Geographic Expansion: Verona Pharma's initial focus is likely on the US and European markets, but expanding into other regions such as Asia-Pacific and Latin America presents a long-term growth opportunity. These regions have a growing prevalence of respiratory diseases and increasing healthcare spending. Partnering with local distributors or establishing a commercial presence in these markets could drive significant revenue growth.
• Lifecycle Management: As ensifentrine approaches commercialization, Verona Pharma can focus on lifecycle management strategies to extend its market exclusivity and maximize revenue. This includes developing new formulations, such as a once-daily version, or exploring new indications for ensifentrine. These strategies can help to maintain a competitive advantage and generate long-term value.
• Strategic Partnerships and Acquisitions: Verona Pharma could pursue strategic partnerships or acquisitions to expand its product pipeline and market reach. Partnering with other pharmaceutical companies could provide access to new technologies, distribution networks, or therapeutic areas. Acquiring smaller biotechnology companies with complementary assets could accelerate Verona Pharma's growth and diversification.

What Opportunities Does VRNA Have?

• Expansion into new respiratory indications (e.g., bronchiectasis).
• Geographic expansion into emerging markets.
• Strategic partnerships with larger pharmaceutical companies.
• Development of new formulations or delivery methods.

What Threats Does VRNA Face?

• Failure to obtain regulatory approval for ensifentrine.
• Competition from existing and emerging therapies.
• Patent expiration.
• Adverse clinical trial results.

What Are VRNA's Competitive Advantages?

• Patent protection for ensifentrine, providing market exclusivity.
• First-in-class dual-inhibitor mechanism of action, differentiating it from existing therapies.
• Clinical trial data demonstrating efficacy and safety, creating a barrier to entry.
• Established relationships with key opinion leaders and healthcare providers in the respiratory field.

What Does VRNA Do?

Verona Pharma plc, established in 2005 and headquartered in London, is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for respiratory diseases with significant unmet medical needs. The company's primary focus is on ensifentrine, a first-in-class, inhaled dual inhibitor of phosphodiesterase (PDE) 3 and PDE4. This unique mechanism of action allows ensifentrine to act as both a bronchodilator and an anti-inflammatory agent within a single molecule. Verona Pharma is currently advancing ensifentrine through Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. The company is developing ensifentrine in three distinct formulations: nebulizer, dry powder inhaler (DPI), and pressurized metered-dose inhaler (pMDI), to cater to a broad range of patient needs and preferences. Verona Pharma aims to improve the lives of patients suffering from respiratory diseases by providing effective and convenient treatment options. The company's strategic focus on ensifentrine and its commitment to clinical development positions it as a key player in the respiratory therapeutics market.

What Products and Services Does VRNA Offer?

• Develops therapies for respiratory diseases.
• Focuses on unmet medical needs in respiratory care.
• Conducts clinical trials to evaluate drug efficacy and safety.
• Seeks regulatory approvals for its drug candidates.
• Aims to commercialize innovative treatments for COPD, asthma, and cystic fibrosis.
• Develops inhaled formulations of ensifentrine (nebulizer, DPI, pMDI).
• Researches and develops new treatments for respiratory conditions.

How Does VRNA Make Money?

• Develops and patents novel pharmaceutical products.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval from agencies like the FDA and EMA.
• Commercializes approved products through sales and marketing efforts, or via partnerships.

What Industry Does VRNA Operate In?

The biotechnology industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The respiratory disease market, in particular, is a large and growing market, driven by factors such as increasing pollution levels, aging populations, and rising prevalence of asthma and COPD. Verona Pharma competes with established pharmaceutical companies and other biotechnology firms developing therapies for respiratory diseases. The success of Verona Pharma depends on its ability to successfully navigate the regulatory landscape, secure patent protection for its products, and effectively commercialize ensifentrine.

Who Are VRNA's Key Customers?

• Patients suffering from chronic obstructive pulmonary disease (COPD).
• Patients with asthma.
• Individuals diagnosed with cystic fibrosis.
• Healthcare providers (physicians, pulmonologists) who prescribe respiratory medications.
• Hospitals and clinics that treat respiratory illnesses.

FY2026 estForward Outlook

Wall Street analysts project Verona Pharma plc revenue of about $777.2M for fiscal 2026, with EPS near $1.19. The estimate reflects 7 contributing analysts.

VRNA Valuation & Market Position

With a $72.7B market cap, Verona Pharma plc sits in the large-cap segment of the market. Relative to its peer group, VRNA's quantitative score of 59/100 is roughly in line with the peer average of 62/100.

ROE -2%Key Financial Metrics

Return on equity for Verona Pharma plc stands at -1.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.7%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.71 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.0%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

Verona Pharma plc's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Company Profile

Verona Pharma plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in London, GB. The company is led by CEO David S. Zaccardelli. VRNA has traded publicly since 2017.

VRNA Financials

VRNA Latest News

No recent news available for VRNA.

VRNA Analyst Consensus

VRNA MoonshotScore

What Investors Ask About Verona Pharma plc (VRNA) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources